Cartilage Repair Using a Hyaluronic Acid-Based Scaffold With Bone Marrow Aspirate Compared With Microfracture for Focal Articular Cartilage Damage of the Hip

NCT04875767 | Withdrawn DMC

• 1 other identifier: CHASE01
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Femoroacetabular impingement (FAI) is a hip disorder resulting from a mismatch of the hip joint, resulting in hip pain and can potentially cause osteoarthritis. As the head of the femur (ball of the hip) and the acetabulum (socket of the hip) impinge or rub together with this mismatch, patients can suffer damage to their articular cartilage which covers both. Currently, the standard of care to surgically treat articular cartilage damage is a procedure called 'microfracture' - where the surgeon makes multiple holes in the bone under the defects causing bone marrow cells and blood from the holes to combine to form a "super clot" that covers the damaged area and is meant to be the basis for new tissue formation or 'fibrocartilage'. However, native articular cartilage is made of hyaline, rather than fibrocartilage, which is a more flexible and durable tissue able to withstand a great deal of force on the hip when it moves. Therefore, a more recently developed strategy that has gained popularity for use in the repair of articular cartilage in the knee involves the implantation of bone marrow aspirate (BMA) along with a scaffold made of hyaluronic acid (HA) in a single-step procedure, with the goal of promoting new hyaline-like tissue. While this has shown promising results in treating knee cartilage damage, this treatment method has yet to be studied in the hip. This randomized controlled trial will evaluate in patients with painful articular cartilage damage of the hip, the effect of implantation of an HA scaffold along with BMA in comparison to microfracture on hip pain and function, cartilage regeneration, and any complications at 24 months post-surgery.

Conditions

Femoroacetabular Impingement; Cartilage Damage

Outcome Measures

Primary Outcomes (1)

• International Hip Outcome Tool-33 (iHOT-33)

  The iHOT-33 is designed to measure hip-specific health-related quality of life changes after treatment of active young patients with hip disorders. The questionnaire has been validated in this patient population and has demonstrated efficacy, reliability, and responsiveness to change.

  24 months

Secondary Outcomes (4)

• Visual Analogue Scale (100-point scale) (VAS)

  24 months

• Euro-Qol 5-D (EQ-5D)

  24 months

• Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART)

  24 months

• Adverse events

  24 months

Study Arms (2)

HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)

EXPERIMENTAL

Those allocated to the scaffold treatment group will have 30 ml of BMA harvested from the ipsilateral iliac crest under fluoroscopic guidance. The hip arthroscopy will then be resumed, and the damaged cartilage lesion will be debrided using a mechanical shaver to remove loose and calcified tissue. Once the walls of the lesion are confirmed to be stable with a probe, the exact size of the defect will be measured for templating of the scaffold. The biodegradable HA-based scaffold (Hyalofast®; Anika Therapeutics, Bedford, MA, USA) will be prepared by cutting it to fit the focal defect. Once the cartilage lesion is dried manually, this scaffold will be implanted into the defect after it has been soaked in the BMA. The scaffold will then be secured to the defect in a press-fit fashion to the surrounding cartilage. In the case where additional fixation of the scaffold is needed, such as uncontained shoulder of cartilage, fibrin glue will be used to secure the scaffold.

Device: HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)

Microfracture

ACTIVE COMPARATOR

As per current standard of care for focal articular cartilage lesions of the acetabulum, the unstable cartilage will be debrided and removed from the subchondral bone using a mechanical shaver until a stable margin is obtained. A ring curette will be used to remove the calcified cartilage layer and create a border of healthy cartilage tissue that can support the marrow clot. Through the mid-anterior portal, specialized 90˚ awls will then be placed with the tip perpendicular to the subchondral bone of the acetabulum, and a mallet will be used to penetrate the subchondral bone with perforations 3 mm deep to access the bone marrow elements. This is done until the defect is homogeneously covered with micro-perforations 2-3 mm apart.

Device: HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)

Interventions

HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA) DEVICE

General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.

HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA); Microfracture

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male and female patients aged 18-40 years
• Hip pain lasting 6 months or more with no relief from documented non-operative modalities
• Cam, Pincer, or Mixed FAI
• Focal articular cartilage defects of the acetabulum on MRI, confirmed to be full thickness (International Cartilage Regeneration and Joint Preservation Society (ICRS) grade 3 or 4) during arthroscopic examination
• Focal acetabular articular cartilage lesions measuring between 1x1 cm2 and 5x5 cm2 on MRI and confirmed on arthroscopic examination
• Patient agrees to participate in the study-specific postoperative rehabilitation protocol
• Patient can speak, read, and understand the language of the site
• Patient has provided informed consent

You may not qualify if:

• Cartilage defects of the femoral head
• Previous surgery on the study hip
• Traumatic chondral injury of the hip from a single event
• Presence of advanced osteoarthritis (Tonnis grade 2 or 3)
• Known hypersensitivity or allergy to hyaluronate
• Evidence of hip dysplasia (i.e. lateral centre edge angle \< 20˚)
• Evidence of acetabular over coverage such as coxa profunda or coxa protrusion
• Immunosuppressive or anti-proliferative medication use
• Chronic pain syndromes
• Significant medical co-morbidities (requiring assistance for activities of daily living (ADLs))
• History of paediatric hip disease
• Uncontrolled diabetes
• Contraindications to MRI imaging (e.g. claustrophobia)
• Patient is involved in ongoing legal or workplace claims
• Patient is incarcerated

Sponsors & Collaborators

• McMaster University: lead

MeSH Terms

Conditions

Femoracetabular Impingement

Condition Hierarchy (Ancestors)

Joint Diseases; Musculoskeletal Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: The outcome assessors and those performing data entry and analysis will be blinded to the treatment allocation. Although patients will not be told which treatment they received, blinding may not be feasible given the intervention group will have an additional bone marrow harvest site incision at the iliac crest.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 29, 2021
• First Posted: May 6, 2021
• Study Start: January 3, 2023
• Primary Completion: November 19, 2024
• Study Completion: November 19, 2024
• Last Updated: November 21, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share